Indium 111 Diethylenetriamine Pentaacetic Acid Scintigraphy in the Identification and Management of Intrathecal Pump Malfunction

June Guillet, Kelsie Cato, Hadyn Williams, Pamela Salazar, Samuel Macomson, Elizabeth Sekul, John Vender

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Intrathecal drug-delivery systems have become widely used tools in the management of refractory chronic pain and spasticity. Because increasing numbers of patients are using these systems, rehabilitation specialists frequently are the initial care providers who identify clinical signs and symptoms indicating possible complications elating to the implanted system. Identification of a pump malfunction often presents a diagnostic challenge. Distinguishing among progression of disease, new organic problems, and/or drug-device complications is critical. The use of nuclear medicine indium 111diethylenetriamine pentaacetic acid (DTPA) studies represents a highly effective, straightforward, minimally invasive way to assess implant function and drug distribution. Objective: To identify patients with suspected intrathecal pump malfunction and todetermine whether the use of indium 111 DTPA is effective in identifying the source of failure. Design: A retrospective review was performed from 2011 to 2012. Setting: The study was performed at Georgia Health Sciences University. Patients: The 23 selected patients had implanted devices for either spasticity or pain and were experiencing symptoms of a possible pump malfunction despite normal radiographic imaging. Twenty-four scintigraphic studies were performed, with malfunction documented in 19 patients. Methods: A standard refill technique was used to inject 0.3 mL of indium 111 DTPA into the pump reservoir. Radionuclide images were reviewed at varying time points up to 48 hours after injection. The extent of radionuclide progression from the pump reservoir to the intrathecal space was evaluated. In cases in which a problem with the implant was identified, correlation with operative findings is described. Results: Normal results of studies ultimately correlated with other clinical issues and confirmed an alternative etiology for the clinical changes noted. In studies with abnormal results, several patterns of failure were identified: restriction of the radionuclide to the pump reservoir, extravasations of tracer into the pump subcutaneous pocket, failure of the tracer to migrate from the subcutaneous catheter to the intrathecal space, and pooling of the tracer in the subcutaneous tissues. In all cases, surgical findings confirmed the suspected mechanism of malfunction as determined by the study. Conclusions: Indium 111 DTPA scintigraphy is a safe, straightforward way to identify and characterize clinical changes associated with intrathecal drug-delivery systems and to guide appropriate and clinical surgical management.

Original languageEnglish (US)
Pages (from-to)32-38
Number of pages7
JournalPM and R
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Pentetic Acid
Indium
Radionuclide Imaging
Radioisotopes
Drug Delivery Systems
Drug Implants
Intractable Pain
Equipment and Supplies
Nuclear Medicine
Subcutaneous Tissue
Chronic Pain
Signs and Symptoms
Disease Progression
Rehabilitation
Catheters
Pain
Injections
Acids
Health
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation
  • Neurology
  • Clinical Neurology

Cite this

Indium 111 Diethylenetriamine Pentaacetic Acid Scintigraphy in the Identification and Management of Intrathecal Pump Malfunction. / Guillet, June; Cato, Kelsie; Williams, Hadyn; Salazar, Pamela; Macomson, Samuel; Sekul, Elizabeth; Vender, John.

In: PM and R, Vol. 5, No. 1, 01.01.2013, p. 32-38.

Research output: Contribution to journalArticle

Guillet, June ; Cato, Kelsie ; Williams, Hadyn ; Salazar, Pamela ; Macomson, Samuel ; Sekul, Elizabeth ; Vender, John. / Indium 111 Diethylenetriamine Pentaacetic Acid Scintigraphy in the Identification and Management of Intrathecal Pump Malfunction. In: PM and R. 2013 ; Vol. 5, No. 1. pp. 32-38.
@article{fe584ad8b01f4b808152937dde919a05,
title = "Indium 111 Diethylenetriamine Pentaacetic Acid Scintigraphy in the Identification and Management of Intrathecal Pump Malfunction",
abstract = "Background: Intrathecal drug-delivery systems have become widely used tools in the management of refractory chronic pain and spasticity. Because increasing numbers of patients are using these systems, rehabilitation specialists frequently are the initial care providers who identify clinical signs and symptoms indicating possible complications elating to the implanted system. Identification of a pump malfunction often presents a diagnostic challenge. Distinguishing among progression of disease, new organic problems, and/or drug-device complications is critical. The use of nuclear medicine indium 111diethylenetriamine pentaacetic acid (DTPA) studies represents a highly effective, straightforward, minimally invasive way to assess implant function and drug distribution. Objective: To identify patients with suspected intrathecal pump malfunction and todetermine whether the use of indium 111 DTPA is effective in identifying the source of failure. Design: A retrospective review was performed from 2011 to 2012. Setting: The study was performed at Georgia Health Sciences University. Patients: The 23 selected patients had implanted devices for either spasticity or pain and were experiencing symptoms of a possible pump malfunction despite normal radiographic imaging. Twenty-four scintigraphic studies were performed, with malfunction documented in 19 patients. Methods: A standard refill technique was used to inject 0.3 mL of indium 111 DTPA into the pump reservoir. Radionuclide images were reviewed at varying time points up to 48 hours after injection. The extent of radionuclide progression from the pump reservoir to the intrathecal space was evaluated. In cases in which a problem with the implant was identified, correlation with operative findings is described. Results: Normal results of studies ultimately correlated with other clinical issues and confirmed an alternative etiology for the clinical changes noted. In studies with abnormal results, several patterns of failure were identified: restriction of the radionuclide to the pump reservoir, extravasations of tracer into the pump subcutaneous pocket, failure of the tracer to migrate from the subcutaneous catheter to the intrathecal space, and pooling of the tracer in the subcutaneous tissues. In all cases, surgical findings confirmed the suspected mechanism of malfunction as determined by the study. Conclusions: Indium 111 DTPA scintigraphy is a safe, straightforward way to identify and characterize clinical changes associated with intrathecal drug-delivery systems and to guide appropriate and clinical surgical management.",
author = "June Guillet and Kelsie Cato and Hadyn Williams and Pamela Salazar and Samuel Macomson and Elizabeth Sekul and John Vender",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.pmrj.2012.07.010",
language = "English (US)",
volume = "5",
pages = "32--38",
journal = "PM and R",
issn = "1934-1482",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Indium 111 Diethylenetriamine Pentaacetic Acid Scintigraphy in the Identification and Management of Intrathecal Pump Malfunction

AU - Guillet, June

AU - Cato, Kelsie

AU - Williams, Hadyn

AU - Salazar, Pamela

AU - Macomson, Samuel

AU - Sekul, Elizabeth

AU - Vender, John

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Intrathecal drug-delivery systems have become widely used tools in the management of refractory chronic pain and spasticity. Because increasing numbers of patients are using these systems, rehabilitation specialists frequently are the initial care providers who identify clinical signs and symptoms indicating possible complications elating to the implanted system. Identification of a pump malfunction often presents a diagnostic challenge. Distinguishing among progression of disease, new organic problems, and/or drug-device complications is critical. The use of nuclear medicine indium 111diethylenetriamine pentaacetic acid (DTPA) studies represents a highly effective, straightforward, minimally invasive way to assess implant function and drug distribution. Objective: To identify patients with suspected intrathecal pump malfunction and todetermine whether the use of indium 111 DTPA is effective in identifying the source of failure. Design: A retrospective review was performed from 2011 to 2012. Setting: The study was performed at Georgia Health Sciences University. Patients: The 23 selected patients had implanted devices for either spasticity or pain and were experiencing symptoms of a possible pump malfunction despite normal radiographic imaging. Twenty-four scintigraphic studies were performed, with malfunction documented in 19 patients. Methods: A standard refill technique was used to inject 0.3 mL of indium 111 DTPA into the pump reservoir. Radionuclide images were reviewed at varying time points up to 48 hours after injection. The extent of radionuclide progression from the pump reservoir to the intrathecal space was evaluated. In cases in which a problem with the implant was identified, correlation with operative findings is described. Results: Normal results of studies ultimately correlated with other clinical issues and confirmed an alternative etiology for the clinical changes noted. In studies with abnormal results, several patterns of failure were identified: restriction of the radionuclide to the pump reservoir, extravasations of tracer into the pump subcutaneous pocket, failure of the tracer to migrate from the subcutaneous catheter to the intrathecal space, and pooling of the tracer in the subcutaneous tissues. In all cases, surgical findings confirmed the suspected mechanism of malfunction as determined by the study. Conclusions: Indium 111 DTPA scintigraphy is a safe, straightforward way to identify and characterize clinical changes associated with intrathecal drug-delivery systems and to guide appropriate and clinical surgical management.

AB - Background: Intrathecal drug-delivery systems have become widely used tools in the management of refractory chronic pain and spasticity. Because increasing numbers of patients are using these systems, rehabilitation specialists frequently are the initial care providers who identify clinical signs and symptoms indicating possible complications elating to the implanted system. Identification of a pump malfunction often presents a diagnostic challenge. Distinguishing among progression of disease, new organic problems, and/or drug-device complications is critical. The use of nuclear medicine indium 111diethylenetriamine pentaacetic acid (DTPA) studies represents a highly effective, straightforward, minimally invasive way to assess implant function and drug distribution. Objective: To identify patients with suspected intrathecal pump malfunction and todetermine whether the use of indium 111 DTPA is effective in identifying the source of failure. Design: A retrospective review was performed from 2011 to 2012. Setting: The study was performed at Georgia Health Sciences University. Patients: The 23 selected patients had implanted devices for either spasticity or pain and were experiencing symptoms of a possible pump malfunction despite normal radiographic imaging. Twenty-four scintigraphic studies were performed, with malfunction documented in 19 patients. Methods: A standard refill technique was used to inject 0.3 mL of indium 111 DTPA into the pump reservoir. Radionuclide images were reviewed at varying time points up to 48 hours after injection. The extent of radionuclide progression from the pump reservoir to the intrathecal space was evaluated. In cases in which a problem with the implant was identified, correlation with operative findings is described. Results: Normal results of studies ultimately correlated with other clinical issues and confirmed an alternative etiology for the clinical changes noted. In studies with abnormal results, several patterns of failure were identified: restriction of the radionuclide to the pump reservoir, extravasations of tracer into the pump subcutaneous pocket, failure of the tracer to migrate from the subcutaneous catheter to the intrathecal space, and pooling of the tracer in the subcutaneous tissues. In all cases, surgical findings confirmed the suspected mechanism of malfunction as determined by the study. Conclusions: Indium 111 DTPA scintigraphy is a safe, straightforward way to identify and characterize clinical changes associated with intrathecal drug-delivery systems and to guide appropriate and clinical surgical management.

UR - http://www.scopus.com/inward/record.url?scp=84872617888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872617888&partnerID=8YFLogxK

U2 - 10.1016/j.pmrj.2012.07.010

DO - 10.1016/j.pmrj.2012.07.010

M3 - Article

VL - 5

SP - 32

EP - 38

JO - PM and R

JF - PM and R

SN - 1934-1482

IS - 1

ER -